340B Drug Pricing Program
The AHA 340B Advocacy Alliance Feb. 22 at 3 p.m. ET will provide an update on the many legal cases and issues surrounding the 340B Drug Pricing Program.
Instead of attacking hospitals and health systems caring for patients during the COVID-19 pandemic, PhRMA should instead focus on lowering the costs of drugs for Americans, writes AHA Executive Vice President Tom Nickels.
The AHA, joined by member hospitals and health systems and other national organizations representing hospitals, filed petitions asking the U.S. Supreme Court to reverse appeals court decisions in two important cases for patients and providers.
America’s hospitals and health systems, and our heroic caregivers, have been on the front lines of the battle against COVID-19 for the past year, working tirelessly to provide needed care to patients and communities.
The AHA, joined by member hospitals and health systems and other national organizations representing hospitals, yesterday filed petitions asking the U.S. Supreme Court to reverse appeals court decisions in two important cases for patients and providers.
The two cases being appealed to the U.S.…
AHA joined by others ask U.S. Supreme Court to hear cases on 340B, hospital outpatient payment cuts
QUESTION PRESENTED: The question presented is whether Chevron deference permits HHS to set reimbursement rates based on acquisition cost and vary such rates by hospital group if it has not collected adequate hospital acquisition cost survey data.
Please contact your representatives and ask them to sign onto a
Plaintiffs' Response to Order to Show Cause Opposition to Defendants' Motion to Dismiss and Reply in Support of Plaintiffs' Motion for a Preliminary Injunction Re: 340B Contract Pharmacy
Order to show Cause RE: Dismissal for Lack of Subject-Matter Jurisdiction